T1	Participants 1866 2040	CONCLUSION In the PemCBev arm, this exploratory analysis showed no significant differences between African Americans and whites for the efficacy outcomes or toxicity profiles
T2	Participants 1146 1237	RESULTS Of 939 intent-to-treat (ITT) patients, 94 were African American and 805 were white.
T3	Participants 767 1015	MATERIALS AND METHODS PointBreak subgroup efficacy and safety data were retrospectively analyzed: African Americans versus whites for PemCBev; PemCBev versus PacCBev in African Americans; and academic versus community settings for African Americans
T4	Participants 308 441	INTRODUCTION African Americans have a greater incidence of lung cancer than whites and have been underrepresented in clinical trials.
T5	Participants 0 305	Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed byÂ Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer
